O’Neill Institute 2025 Colloquium Session 12: Innovative HIV Prevention and Treatment: Can a Twice-Yearly PrEP Injection Curb the HIV Pandemic?

Join us for an in-depth discussion on Lenacapavir, a groundbreaking long-acting injectable PrEP formulation administered just twice a year. This session will examine its potential to transform HIV prevention on a global scale, looking at the latest clinical evidence, regulatory pathways, and the access barriers that may shape its rollout, especially in low-resource settings. The program will feature a special keynote address followed by a panel discussion with leading experts in HIV prevention and global health, exploring how innovation, policy, and equity intersect in the next frontier of HIV response.